135 episodes

A monthly audio round-up detailing the contents of the latest issue of DTB.

DTB podcast BMJ Group

    • Science
    • 4.5 • 21 Ratings

A monthly audio round-up detailing the contents of the latest issue of DTB.

    Overprescribing, overuse of short-acting beta agonists, inflammatory bowel disease in pregnancy

    Overprescribing, overuse of short-acting beta agonists, inflammatory bowel disease in pregnancy

    In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the February 2022 issue of DTB. They talk about some of the details from a national report on overprescribing and discuss its implications (https://dtb.bmj.com/content/60/2/18). The editors review a study that highlighted overprescribing of short-acting beta agonists in people with asthma (https://dtb.bmj.com/content/60/2/21). They also discuss an article on prescribing for women of childbearing age who have inflammatory bowel disease and managing medicines during pregnancy (https://dtb.bmj.com/content/60/2/24).
    Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

    • 21 min
    January 2022 - Molnupiravir, potentially harmful prescribing and antidepressant withdrawal reactions

    January 2022 - Molnupiravir, potentially harmful prescribing and antidepressant withdrawal reactions

    In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the January 2022 issue of DTB. They discuss the UK Medicines and Healthcare products Regulatory Agency's decision to license the oral antiviral drug molnupiravir (Lagevrio) and the paucity of publicly available clinical trial data - https://dtb.bmj.com/content/60/1/2. The editors talk about a study that highlighted potentially inappropriate prescribing in middle-aged adults - https://dtb.bmj.com/content/60/1/6. They also review an article on some of the challenges facing people when they try to stop taking antidepressants - https://dtb.bmj.com/content/60/1/7.
    Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

    • 28 min
    Dec 2021 - Overprescribing, BP monitor accuracy, topical steroids, and bremelanotide and flibanserin

    Dec 2021 - Overprescribing, BP monitor accuracy, topical steroids, and bremelanotide and flibanserin

    In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the December issue of DTB. They discuss a recently published national report on overprescribing of medicines. The editors talk about a study that assessed the accuracy of home blood pressure monitors (https://dtb.bmj.com/content/59/12/179) and highlight a safety alert on topical steroid withdrawal reactions (https://dtb.bmj.com/content/59/12/184). They also review an article on the US Food and Drug Administration's decision to license bremelanotide and flibanserin for 'hypoactive sexual desire disorder’ in women (https://dtb.bmj.com/content/59/12/185).
    Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

    • 22 min
    November 2021 - Drugs to avoid, penicillin allergy and a new drug for osteoporosis

    November 2021 - Drugs to avoid, penicillin allergy and a new drug for osteoporosis

    In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the November issue of DTB. They discuss a French initiative that identifies a range of drugs that should not be prescribed (https://dtb.bmj.com/content/59/11/162) and talk about the difficulty of assessing whether patients' penicillin allergy records are correct (https://dtb.bmj.com/content/59/11/163). They also review an article on the use of romosozumab for osteoporosis (https://dtb.bmj.com/content/59/11/169). They begin by highlighting DTB's blog for World Evidence-Based Healthcare Day (https://worldebhcday.org/) on the role of independent drug bulletins during an info-demic.
    Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

    • 19 min
    October 2021 - Desogestrel POM to P, PCI in stable IHD, and migraine in pregnancy

    October 2021 - Desogestrel POM to P, PCI in stable IHD, and migraine in pregnancy

    In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the October issue of DTB. They discuss the impact of making desogestrel contraceptives available for purchase from pharmacies (https://dtb.bmj.com/content/59/10/146) and talk about the role of percutaneous coronary intervention in patients with stable ischaemic heart disease (https://dtb.bmj.com/content/59/10/150). They also review an article about managing migraine in pregnancy (https://dtb.bmj.com/content/59/10/152). They begin by highlighting the decision to remove pregabalin from the Northern Ireland formulary for neuropathic pain.
    Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

    • 21 min
    September 2021: Aducanumab for Alzheimer's, antibiotics, shared-decision making, and dental health

    September 2021: Aducanumab for Alzheimer's, antibiotics, shared-decision making, and dental health

    In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the September issue of DTB. They discuss the US FDA's controversial decision to license aducanumab for Alzheimer's disease (https://dtb.bmj.com/content/59/9/130) and consider barriers to prescribing shorter courses of antibiotics in primary care (https://dtb.bmj.com/content/59/9/131). The editors also highlight the impact that some medicines have on oral health and dental treatment (https://dtb.bmj.com/content/59/9/135).
    Before all of that though, the recent NICE's guideline on shared decision making.
    Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

    • 23 min

Customer Reviews

4.5 out of 5
21 Ratings

21 Ratings

DrRosW ,

Always interesting

As a GP, I listen to a lot of medical podcasts. This is one of my favourite. They have a healthy scepticism of drugs and therapeutics and the industry, and look carefully at the evidence. I think this is the BMJ group’s best podcast.

JB791 ,

Great podcast for prescribers- highly recommended

An interesting and useful podcast for prescribers- both for the specific issues and the general principles.

Top Podcasts In Science

BBC
BBC Radio 4
BBC Radio 4
Hannah Fry
BBC Radio 4
Hidden Brain

You Might Also Like

NB Medical Education
BMJ Group
Primary Care Knowledge Boost
Dr Rachel Morris
BBC Radio 4
medicsmoney